Trial Profile

High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
Indications Acute coronary syndromes; Hypercholesterolaemia
Focus Registrational; Therapeutic Use
Acronyms HUYGENS
Sponsors Amgen

Most Recent Events

01 Apr 2025 Results(n=112) evaluating effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome published in the Atherosclerosis.
27 Aug 2021 According to an Amgen media release, data from this trial are being presented during an oral presentation at ESC Congress 2021, organized by the European Society of Cardiology.
27 Aug 2021 Results published in an Amgen Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com